Healthcare
Live Price
Offline$27.97
-13.38% today
1Y Change
+506.95%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tango Therapeutics, Inc. (TNGX) is a Healthcare stock with a market cap of $2.44B and listed on NASDAQ. The stock last traded around $27.97 and up 507.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +48.3%, EPS growth of +26.9%, a dividend yield of 0.0%. What stands out right now is revenue +48.3%, EPS +26.9%, free cash flow -5.8% with operating margin -178.4% and ROIC -29.3%. Valuation already assumes a fairly strong business story at price/sales 39.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TNGX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TNGX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TNGX Max Drawdown
-29.24%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TNGX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$37.0M
+49.0% YoY
FY Net Income
-$58.2M
+46.2% YoY
Free Cash Flow
-$61.4M
+47.4% YoY
Revenue Growth
+48.3%
EPS Growth
+26.9%
Gross Margin
97.3%
Net Margin
-162.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 62M | 42M | 37M | 25M | 37M |
| Gross Profit | 60M | 42M | 37M | 25M | 37M |
| Operating Income | -111M | -146M | -114M | -111M | -58M |
| EBITDA | -109M | -143M | -112M | -109M | -57M |
| Net Income | -102M | -130M | -102M | -108M | -58M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 112M | 70M | 66M | 60M | 143M |
| Total Assets | 399M | 316M | 403M | 436M | 500M |
| Total Liabilities | 53M | 117M | 149M | 187M | 155M |
| Shareholder Equity | 346M | 200M | 253M | 249M | 345M |
| Total Debt | 34M | 36M | 39M | 41M | 2M |
| Net Debt | -79M | -33M | -27M | -19M | -141M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
60M
+45.4% YoY
Capital Expenditures
2M
+76.1% YoY
Free Cash Flow
61M
+47.4% YoY
Key ratios
Gross Margin
97.3%
Operating Margin
-178.4%
Net Margin
-162.9%
ROE
-50.3%
Debt / Equity
0.10x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.